In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572

AIDS

Volumn 24, Issue 17, 2010, Pages 2753-2755

  Charpentier, Charlotte ^a   Larrouy, Lucile ^a   Collin, Gilles ^a   Damond, Florence ^a   Matheron, Sophie ^a   Chêne, Geneviève ^b   Nie, Ting ^c   Schinazi, Raymond ^c   Brun Vézinet, Françoise ^a   Descamps, Diane ^a  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CYSTEINE; GLUTAMINE; GLYCINE; INTEGRASE INHIBITOR; RALTEGRAVIR; S/GSK 1349572; SERINE; THREONINE; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VITRO STUDY; MUTANT; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; WILD TYPE;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-2; HUMANS; MUTATION;

EID: 78349311194     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833f9e36     Document Type: Article

References (14)

1. Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother 2008; 52:1545-1548.
2. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther 2004; 9:57-65.
3. Tantillo C, Ding J, Jacobo-Molina A, Nanni RG, Boyer PL, Hughes SH, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243:369-387.
4. Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the in-tegrase inhibitors raltegravir and elvitegravir in vitro. J Anti-microb Chemother 2008; 62:914-920.
5. Garrett N, Xu L, Smit E, Ferns B, El-Gadi S, Anderson J. Raltegravir treatment response in an HIV-2 infected patient: a case report. AIDS 2008; 22:1091-1092.
6. Salgado M, Toro C, Simón A, Garrido C, Blanco F, Soriano V, et al. Mutation N155H in HIV-2 integrase confers high pheno-typic resistance to raltegravir and impairs replication capacity. J Clin Virol 2009; 46:173-175.
7. Lalezari J, Sloan L, Dejesus E, Hawkins T, Mccurdy L, Song I, et al. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-näive HIV-1-infected patients [Abstract TUAB105].In: 5th IAS Conference on HIVPathogenesis, Treatment and Prevention. Cape Town, South Africa, July 2009.
8. Damond F, Collin G, Descamps D, Matheron S, Pueyo S, Taieb A, et al. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J Clin Microbiol 2005; 43:4234-4236.
9. Lataillade M, Chiarella J, Kozal MJ. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 2007; 12:563-570.
10. Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.JAntimi-crob Chemother 2009; 63:795-804.
11. Quercia R, Dam E, Perez-Bercoff D, Clavel F. Selective-advan- tageprofileof human immunodeficiencyvirustype 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes. J Virol 2009; 83:10245-10249.
12. Sato A, Kobayashi M, Yoshinaga T, Fujiwara T, Underwood M, Johns B, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor [Abstract WEPEA097]. In: 5th IAS Confer-ence on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 2009.
13. Seki T, Kobayashi M, Wakasa-Morimoto C, Yoshinaga T, Sato A, Fujiwara T, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones [Abstract 555]. In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, February 2010.
14. Underwood M, Johns B, Sato A, Fujiwara T, Spreen W. S/GSK1349572: a next generation integrase inhibitor with activ-ity against integrase inhibitor resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy [Abstract WEPEA098]. In: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 2009